Systematic Review of miRNA as Biomarkers in Alzheimer's Disease.

Swarbrick S, Wragg N, Ghosh S, Stolzing A. · 2019

Read Systematic Review of miRNA as Biomarkers in Alzheimer's Disease. by Swarbrick S, Wragg N, Ghosh S, Stolzing A. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6682547.txt.

Introduction

Swarbrick and co-authors systematically review microRNAs as biomarkers in Alzheimer's disease. Their review appears in Molecular Neurobiology. Small non-coding RNAs are deregulated in patients' blood. The reviewers extracted every significantly deregulated blood microRNA. They cross-referenced these against brain changes at Braak stage III. The overlap yielded a panel of ten microRNAs. Names include mir-107, mir-146a, and mir-125b. The panel may shift early in disease. That could be twenty years before symptoms.

Network analysis mapped the panel's associations. Immune function and cell cycle regulation featured. Stress responses and Wnt signalling also appeared. Cellular senescence and Rho GTPases completed the list. Early blood biomarkers remain an urgent need.

Catalog record

CREATORSwarbrick S, Wragg N, Ghosh S, Stolzing A.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6682547

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Systematic Review of miRNA as Biomarkers in Alzheimer’s Disease By S. Swarbrick, N. Wragg, S. Ghosh, Alexandra Stolzing Published in: Molecular Neurobiology DOI: 10.1007/s12035-019-1500-y ABSTRACT Currently there are 850,000 people with Alzheimer’s disease in the UK, with an estimated rise to 1.1 million by 2025. Alzheimer’s disease is characterised by the accumulation of amyloid-beta plaques and hyperphosphorylated tau in the brain causing a progressive decline in cognitive impairment. Small non-coding microRNA (miRNA) sequences have been found to be deregulated in the peripheral blood of Alzheimer patients. A systematic review was conducted to extract all miRNA found to be significantly deregulated in the peripheral blood. These deregulated miRNAs were cross-referenced against the miRNAs deregulated in the brain at Braak Stage III. This resulted in a panel of 10 miRNAs (hsa-mir-107, hsa-mir-26b, hsa-mir-30e, hsa-mir-34a, hsa-mir-485, hsa-mir200c, hsa-mir-210, hsa-mir-146a, hsa-mir-34c, and hsa-mir-125b) hypothesised to be deregulated early in Alzheimer’s disease, nearly 20 years before the onset of clinical symptoms. After network analysis of the 10 miRNAs, they were found to be associated with the immune system, cell cycle, gene expression, cellular response to stress, neuron growth factor signalling, wnt signalling, cellular senescence, and Rho GTPases. DEMENTIA Dementia is a common syndrome in people over 65 years of age and is characterised by a progressive decline in memory and other abilities [1]. In 2014, there were 850,000 people living with Alzheimer’s disease in the UK, costing the economy £26.3 billion a year. Due to the ageing population, this is set to rise to over 1.1 million people with Alzheimer’s disease in 2025 [2]. The Prime Ministers Challenge on Dementia 2020, established by the UK Government, found in 2010/11 that only 42% of estimated dementia sufferers in England had a formal diagnosis [3]. In 2016, the diagnosis rate increased to 67% [4]. This has been attributed to an increased public awareness of dementia, a reduction in the stigma associated with dementia, and an increase in dementia research. Due to the nature of dementia, the accuracy of the diagnosis correlates with the severity of the symptoms and varies from 9 to 41% [4]. Onset of dementia can occur 20–30 years before the first symptoms appear [5]; therefore, the earlier a diagnosis can be made, the less developed the degeneration will be, increasing the probability of a successful treatment. Alzheimer’s Disease Alzheimer’s disease is the most common form of dementia accounting for 62% of the dementia patients [2] and is characterised by the presence of amyloid plaques and hyperphosphorylated tau in the brain. In 1991, Braak and Braak mapped the movement of both amyloid-β and hyperphosphorylated tau in the brain during the progression of the disease [6]. The movement of amyloid was split into three Stages (A–C) and that of tau into six (I–VI), as shown in Fig. 1.Fig. 1Schematic of the Braak and Braak amyloid and tau stages during the progression of Alzheimer’s disease. Mild, moderate, and severe correspond to the density of amyloid/tau protein Amyloid deposits are mainly found in the isocortex of the cerebral cortex. The plaques are not uniform in shape or size and early stage accumulation suffers from inter-individual variation. The amyloid deposition develops before the onset of tau. However, the presence of amyloid does not mean that tau pathology will develop [6]. During Stage A, amyloid is found in the base layer of the frontal, temporal, and occipital lobes. In Stage B, amyloid progresses to almost all isocortex areas and during Stage C, amyloid becomes densely packed [6]. Tau Braak Stages correlate with the progression of Alzheimer’s disease. It is estimated that it can take 48 years to develop from Braak Stage I to Braak Stage V in which Alzheimer’s disease symptoms are apparent. A large proportion of that time is when the disease is non-symptomatic as it can take 30 years to progress from Braak Stage I to Stage III [5]. Braak Stages I and II are centred around the transentorhinal region with Stage II being more densely packed with tau pathology than Stage I. At Stage III, the pathology moves into the entorhinal region with low levels of tau seen in CA1 of the hippocampus and no or mild changes present in the isocortex [6]. The hippocampus is responsible for episodic memory, which is memory of autobiographical events [7]. This corresponds with early symptoms seen in Alzheimer’s disease and is defined as mild cognitive impairment (MCI). Patients that fit this definition are 3–5 times more likely to develop dementia within 3–5 years [8]. At Stage IV, there is increased pathology in the entorhinal region and CA1 hippocampus. At this stage, there is no detectable brain atrophy, and the pathology does not meet the criteria for neuropathologic diagnosis of Alzheimer’s disease. At Stage V, tau is found in almost all areas of the hippocampus and isocortex, with the areas becoming severely affected by Stage VI. Involvement of the isocortex corresponds to late Alzheimer’s disease and clinical diagnosis [6]. Alzheimer disease symptoms have been classified by criteria published in 1984 by both the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Group (ADRDG). It concludes that a definitive diagnosis can only be given when histological analysis by biopsy or autopsy has been conducted [1]. If a biopsy cannot be conducted, then a possible or probable diagnosis is given. A probable diagnosis has a sensitivity of 81% and specificity of 70%, a possible diagnosis has a sensitivity of 93% and specificity of 48% [9]. Sensitivity is the ability to distinguish between normal and Alzheimer’s disease, while specificity is the capability to differentiate Alzheimer’s disease from other types of dementia. Diagnostic Techniques for Alzheimer’s Disease An ideal diagnostic technique for Alzheimer’s disease would be that which can identify the disease with adequate reliability considerable time before the onset of symptoms for treatments to be effective, and which is minimally invasive, low-cost, and easy to be applied for mass screening. Current diagnostic techniques for Alzheimer’s disease primarily include cognitive testing [10], neuroimaging [11], and biomarker detection [12]. Other more recently reported diagnostic tests include retinal imaging of amyloid beta, structural changes in the retina [13, 14], and alterations in an Alzheimer patient’s sense of smell [15]. Cognitive testing, for example questionnaires like the mini mental state examination (MMSE), is the most commonly used tool to asses a patient’s symptoms for Alzheimer’s disease [16]. Therefore, cognitive testing is unable to diagnose the disease in the pre-symptomatic stage [17]. Neuroimaging diagnosis, for example magnetic resonance imaging, looks for hippocampal atrophy [18]. However, this is an expensive and specialised technique, which is logistically challenging to be used for mass screening. Detection of biomarkers in patients is heavily reported for cerebrospinal fluid (CSF) and peripheral blood [references]. Other biological samples, such as urine [19], breath [20], and saliva [21, 22], have the potential for biomarker detection although they are less prominent in the literature. CSF requires an invasive lumbar puncture procedure under general anaesthetic with common side effects including mild to moderate headache in up to 46% of cases [23–25]. The most commonly reported CSF assay looks for a decrease in amyloid-beta 42 and increased levels of total tau and phosphorylated tau. The test’s sensitivity ranges between 68 and

Read the complete text